Emergent BioSolutions (NYSE:EBS) Downgraded to Hold Rating by StockNews.com

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research note released on Wednesday.

Several other equities research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday. Benchmark increased their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Stock Down 9.3 %

Shares of NYSE EBS opened at $5.80 on Wednesday. Emergent BioSolutions has a 52-week low of $1.82 and a 52-week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock has a market cap of $314.00 million, a P/E ratio of -1.41 and a beta of 1.62. The firm has a 50 day moving average price of $9.43 and a 200 day moving average price of $9.02.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. During the same period last year, the firm posted ($0.77) earnings per share. Analysts expect that Emergent BioSolutions will post -0.63 EPS for the current year.

Institutional Trading of Emergent BioSolutions

Several hedge funds and other institutional investors have recently modified their holdings of EBS. B. Riley Wealth Advisors Inc. boosted its position in shares of Emergent BioSolutions by 21.9% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 41,800 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 7,500 shares during the period. Alpine Global Management LLC bought a new stake in Emergent BioSolutions in the 4th quarter valued at approximately $112,000. Two Sigma Advisers LP boosted its position in Emergent BioSolutions by 14.1% during the 4th quarter. Two Sigma Advisers LP now owns 656,500 shares of the biopharmaceutical company’s stock worth $6,276,000 after acquiring an additional 81,000 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Emergent BioSolutions by 13.9% during the 4th quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company’s stock worth $8,095,000 after acquiring an additional 103,574 shares in the last quarter. Finally, State of Wyoming raised its holdings in shares of Emergent BioSolutions by 118.2% in the fourth quarter. State of Wyoming now owns 39,076 shares of the biopharmaceutical company’s stock valued at $374,000 after purchasing an additional 21,165 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.